ArticleClinical rheumatology2025

Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: A multicenter retrospective study.

Salim Mısırcı et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.